Satellite Dialysis Greenbrae is a medicare approved dialysis facility center in Greenbrae, California and it has 23 dialysis stations. It is located in Marin county at 565 Sir Francis Drake Blvd., Greenbrae, CA, 94904. You can reach out to the office of Satellite Dialysis Greenbrae at (415) 924-8622. This dialysis clinic is managed and/or owned by Satellite Healthcare. Satellite Dialysis Greenbrae has the following ownership type - Non-Profit. It was first certified by medicare in August, 1977. The medicare id for this facility is 052526 and it accepts patients under medicare ESRD program.
Name | Satellite Dialysis Greenbrae |
---|---|
Location | 565 Sir Francis Drake Blvd., Greenbrae, California |
No. of Dialysis Stations | 23 |
Medicare ID | 052526 |
Managed By | Satellite Healthcare |
Ownership Type | Non-Profit |
Late Shifts | Yes |
565 Sir Francis Drake Blvd., Greenbrae, California, 94904 | |
(415) 924-8622 | |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
NPI Number | 1164493276 |
Organization Name | Satellite Dialysis |
Doing Business As | Satellite Healthcare Inc |
Address | 565 Sir Francis Drake Blvd Greenbrae, California, 94904 |
Phone Number | (415) 924-8622 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 67% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 16% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 17% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 70% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 14% |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 73% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 15% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 12% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 85% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 7% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 12% |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 79% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 21% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 87% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 5% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 12% |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
Dialysis patients with Hemoglobin data | 55 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 18 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 84 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 735 |
Percentage of adult patients getting regular hemodialysis at the center | 96 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
Adult patients getting regular peritoneal dialysis at the center | 1 |
Adult patient months included in Kt/V greater than or equal to 1.7 | 12 |
Percentage of adult patients getting regular peritoneal dialysis at the center | |
Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Satellite Dialysis Greenbrae with elevated calcium levels.
Patients with hypercalcemia | 95 |
Hypercalcemia patient months | 842 |
Patients with Serumphosphor | 94 |
Patients with Serumphosphor less than 3.5 mg/dL | 7 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
Patients with Serumphosphor greater than 7 mg/dL | 19 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 69 |
Patient months included in arterial venous fistula and catheter summaries | 612 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 66 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 78 |
Hospitalization Rate in facility | 158 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 278.7 |
Hospitalization Rate: Lower Confidence Limit | 92.3 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Satellite Dialysis Greenbrae were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 13.1 (Better than Expected) |
Readmission Rate: Upper Confidence Limit | 22.7 |
Readmission Rate: Lower Confidence Limit | 6.4 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Satellite Dialysis Greenbrae get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .16 (Better than Expected) |
SIR: Upper Confidence Limit | .76 |
SIR: Lower Confidence Limit | .01 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Satellite Dialysis Greenbrae's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 64 |
Transfusion Rate in facility | 37.5 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 96.4 |
Transfusion Rate: Lower Confidence Limit | 16.4 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Satellite Dialysis Greenbrae lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 451 |
Mortality Rate in facility | 13.6 (As Expected) |
Mortality Rate: Upper Confidence Limit | 17.8 |
Mortality Rate: Lower Confidence Limit | 10.3 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago
Satellite Dialysis Greenbrae Location: 565 Sir Francis Drake Blvd., Greenbrae, California, 94904 Phone: (415) 924-8622 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex."
ConAgra Foods, Inc., one of North America's leading food makers, announced today new research indicating that a daily snack of Orville Redenbacher's 94 percent fat-free SmartPop!® popcorn can help dieters maintain reduced calorie eating plans while still feeling full and satisfied. In the study, 94 percent of participants said the daily 100-calorie snack of 100 percent whole grain popcorn helped satisfy hunger and 85 percent credited SmartPop! with helping them stay on track with weight loss.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
Santarus, Inc. today announced that the budesonide MMX Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week Meeting being held at McCormick Place in Chicago on May 7-10, 2011.
› Verified 9 days ago